Lower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care Testing

From directly observed therapy studies, urine tenofovir (TFV) levels were 74% lower when taking tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate. Urine TFV remains quantifiable across a range of TAF adherence patterns, but a separate point-of-care lateral flow immunoassay with a lower TF...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Kelly A, Niu, Xin, Glidden, David V, Castillo-Mancilla, Jose R, Yager, Jenna, MaWhinney, Samantha, Morrow, Mary, Okochi, Hideaki, Cressey, Tim R, Drain, Paul K, Gandhi, Monica, Anderson, Peter L, Spinelli, Matthew A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286091/
https://www.ncbi.nlm.nih.gov/pubmed/34285929
http://dx.doi.org/10.1093/ofid/ofab200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286091/
https://www.ncbi.nlm.nih.gov/pubmed/34285929
http://dx.doi.org/10.1093/ofid/ofab200

Ejemplares similares